醋酸烯诺孕酮
| 中文名称 | 醋酸烯诺孕酮 |
|---|---|
| 中文同义词 | 醋酸烯诺孕酮;醋酸烯诺孕酮(ST-1435);烯诺孕酮醋酸酯;(8R,9S,10R,13S,14S,17R)-17-乙酰基-13-甲基-16-亚甲基-3-氧代-2,3,6,7,8,9,10,11,12,13,14,15,16,17-十四氢-1H-环戊[A]菲-17-乙酸酯;醋酸烯诺孕酮,10 MM DMSO 溶液;Nestorone醋酸烯诺孕酮 |
| 英文名称 | Nestoron |
| 英文同义词 | ST 1435;NESTORON;17-Hydroxy-16-methylene-19-norpregn-4-ene-3,20-dione acetate;Elcometrine;17-(ACETYLOXY)-16-METHYLENE-19-NORPREGN-4-ENE-20-DIONE;16-Methylene-17-hydroxy-19-norpregn-4-ene-3,20-dione acetate;16-Methylene-17-alpha-acetoxy-19-nor-4-pregnene-3,20-dione;19-Norpregn-4-ene-3,20-dione, 17-(acetyloxy)-16-methylene- (9ci) |
| CAS号 | 7759-35-5 |
| 分子式 | C23H30O4 |
| 分子量 | 370.48 |
| EINECS号 | |
| 相关类别 | 生物化工;API |
| Mol文件 | 7759-35-5.mol |
| 结构式 |  |
醋酸烯诺孕酮 性质
| 熔点 | 178-179° |
|---|---|
| 比旋光度 | D21 -105° (c = 1.2 in chloroform) |
| 沸点 | 420.37°C (rough estimate) |
| 密度 | 1.0550 (rough estimate) |
| 折射率 | 1.4433 (estimate) |
| 储存条件 | 2-8°C |
| 溶解度 | DMSO：可溶，5mg/mL，澄清 |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| InChI | InChI=1S/C23H30O4/c1-13-11-21-20-7-5-16-12-17(26)6-8-18(16)19(20)9-10-22(21,4)23(13,14(2)24)27-15(3)25/h12,18-21H,1,5-11H2,2-4H3/t18-,19+,20+,21-,22-,23-/m0/s1 |
| InChIKey | CKFBRGLGTWAVLG-GOMYTPFNSA-N |
| SMILES | C1(=O)C=C2[C@]([H])(CC1)[C@]1([H])[C@]([H])([C@@]3([H])[C@@](CC1)(C)[C@@](OC(C)=O)(C(=O)C)C(=C)C3)CC2 |
Nestoron (ST-1435) 是一种 19-norprogesterone 衍生物，对 progesterone receptors 具有高亲和力和选择性，是一种高度选择性和有效的孕激素，可用作激素避孕药。
Progesterone Receptors
Nestoron (400 μCi 3 H Nestoron/kg BW; subcutaneous injection; female Sprague-Dawley rats) treatment results in the C max in the blood and plasma are 58.1 and 95.5 ng equiv. 3 H Nestoron/g, with t 1/2 of 15.6 hours. Approximately, 81.4% and 7.62% of the administered dose is excreted via feces and urine, respectively.
| Animal Model: | 27 adult, female, Sprague-Dawley rats (200-225 g; age: 8 weeks) |
| Dosage: | 400 μCi 3 H Nestorone/kg BW |
| Administration: | Subcutaneous injection (Pharmacokinetic study) |
| Result: | The mean peak concentrations of radioactivity (C max ) in the blood and plasma were 58.1 and 95.5 ng equiv./g, with t 1/2 of 15.6 hours. Approximately, 81.4% and 7.62% of the administered dose was excreted via feces and urine, respectively. |
安全信息
| WGK Germany | 3 |
|---|